It is a critical moment for adoptive cell therapies. Clinical progress has been made with Chimeric Antigen Receptors (CAR), T Cell Receptors (TCR), and Tumor Infiltrating Lymphocytes (TIL), making these therapies the frontrunner for curing immune-based diseases. Still, many challenges remain. The Third Annual Adoptive T Cell Therapy event will bring together immunotherapy veterans and visionaries to not just address those challenges, but to provide solutions and showcase emerging opportunities. This years event will address topics such as developing adoptive cell therapies for solid tumors as well as new targets of interest. Emphasis will be placed on clinical case studies to further the understanding of T cell receptors and their biology. Overall, this event will uncover the critical components needed to make adoptive T cell therapies viable.
Day 1 | Day 2 | Download Brochure
WEDNESDAY, APRIL 27
7:00 am Registration and Morning Coffee
8:00 Chairpersons Remarks
Laszlo G. Radvanyi, Ph.D., CSO, Lion Biotechnologies
8:10 Late Breaking Presentation
8:40 The State-of-the-Art with T cell Receptor-Based Cancer Immunotherapies
Andrew K. Sewell, Ph.D., Distinguished Research Professor, Wellcome Trust Senior Investigator; Research Director, Institute of Infection and Immunity, Henry Wellcome Building, Cardiff University School of Medicine
The ab TCR enables cytotoxic T cells to scan the cellular proteome for anomalies from the cell surface. Tumor-specific TCRs can access a far greater range of targets than are available for antibodies. Engineered TCRs can be used in gene therapy and soluble molecule approaches. Next generation strategies allow circumvention of HLA-restriction. I will discuss future directions in the use of engineered T cells and TCRs in cancer immunotherapy.
9:10 Tumor Infiltrating Lymphocytes for Metastatic Cutaneous and Non-Cutaneous Melanoma: A UK Perspective
John S. Bridgeman, Ph.D., Director, Cell Therapy Research, Cellular Therapeutics Ltd.
We have established the UKs only GMP-compliant and MHRA (Medicines and Healthcare Products Regulatory Agency) licensed unit capable of producing multiple T cell product types (CAR or TCR-modified and natural T cells (TIL)) using clean room free technology. This unit has produced melanoma-derived TIL products which have been successfully returned to patients. This study supports the success of melanoma TIL therapy seen in other centers worldwide and suggests that this is a viable means of treating a disease which has few effective options.
9:40 Design of a Highly Efficacious, Mesothelin-Targeting CAR for Treatment of Solid Tumors
Boris Engels, Ph.D., Investigator, Exploratory Immuno-Oncology, Novartis Institutes for Biomedical Research
The treatment of solid tumors with CAR T cells has shown to be challenging. We describe the design of a fully human CAR targeting mesothelin, a tumor associated antigen overexpressed in mesothelioma, pancreatic and ovarian cancer. The screen of a scFv pool has identified two scFvs, which show enhanced efficacy as CARs, superior to what is currently being used by several groups. We have performed in-depth characterization of the scFvs and CARs to gain insight into structure-activity relationships, which may influence CAR design and efficacy.
10:10 Coffee Break in the Exhibit Hall with Poster Viewing
10:55 ACTR (Antibody Coupled T Cell Receptor): A Universal Approach to T cell Therapy
Seth Ettenberg, Ph.D., CSO, Unum Therapeutics
Fusing the ectodomain of CD16 to the co-stimulatory and signaling domains of 41BB and CD3z generates an Antibody Coupled T cell Receptor (ACTR). T cells expressing this receptor show powerful anti-tumor cytotoxicity when co-administered with an appropriate tumor-targeting antibody. Such cells have potential utility as a therapy to treat a wide range of cancer indications. We will describe efforts specifically targeting B-cell malignancies using a combination of ACTR T cells with rituximab.
11:25 Strategies to Optimize Tumor Infiltrating Lymphocytes (TIL) for Adoptive Cell Therapy
Shari Pilon-Thomas, Ph.D., Assistant Professor, Department of Immunology, Moffitt Cancer Center
Adoptive cell therapy (ACT) with tumor-infiltrating lymphocytes (TIL) has emerged as a powerful immunotherapy for cancer. TIL preparation involves surgical resection of tumors and in vitro expansion of TIL from tumor fragments. ACT depends upon the presence of TIL in tumors, successful expansion of TIL, and effective activation and persistence of T cells after infusion. In this presentation, I will discuss optimization of TIL infiltration into tumors and TIL expansion for ACT in melanoma and other cancers.
11:55 Engineered T Cell Receptors for Adoptive T Cell Therapy in Solid Tumors
Jo Brewer, Ph.D., Director, Cell Research, Adaptimmune Ltd.
NY-ESO-1 is a cancer antigen that is expressed by a wide array of solid and hematological tumors. An enhanced affinity TCR that recognizes this antigen is currently in Phase I/II trials for synovial sarcoma, multiple myeloma, melanoma, ovarian and esophageal cancers. Early clinical data demonstrate encouraging responses and a promising benefit/risk profile.
12:25 pm Cell Based Engineering of TCRs and CARs Using in vitro V(D)J Recombination
Michael Gallo, President, Research, Innovative Targeting Solutions
The ability to generate antibodies and TCRs specific to a MHC/peptide complex provides for new therapeutic opportunities. A novel approach using in vitro V(D)J recombination has been shown to be a robust strategy for targeting these ultra-rare epitopes by generating large de novo repertoires of fully human antibodies, CARs, or T-cell receptors on the surface of mammalian cells. The presentation highlights the advantages of cell based engineering for the generation of cell based adoptive therapies.
12:55 Luncheon Presentation (Sponsorship Opportunity Available) or Enjoy Lunch on Your Own
1:55 Session Break
2:10 Chairpersons Remarks
Jonathan Schneck, Ph.D., M.D., Professor, Pathology, Medicine and Oncology, Johns Hopkins
2:15 Artificial APCs: Enabling Adoptive T Cell Therapies
Marcela V. Maus, M.D., Ph.D., Director, Cellular Immunotherapy, Mass General Hospital Cancer Center
Adoptive T cell therapies require ex vivo T cell culture systems, which can include artificial antigen presenting cells. We will review several types of natural and artificial APCs and how they can be optimized to generate strong memory and effector T cells usable for adoptive transfer.
2:45 Immunoengineering of Artificial Antigen Presenting Cells, aAPC: From Basic Principles to Translation
Jonathan Schneck, Ph.D., M.D., Professor, Pathology, Medicine and Oncology, Johns Hopkins
Artificial antigen presenting cells (aAPCs) are immuno-engineered platforms which advance adoptive immunotherapy by reducing the cost and complexity of generating tumor-specific T cells. Our new approach, termed Enrichment and Expansion (E+E), utilizes paramagnetic nanoparticle-based aAPCs to rapidly expand both shared tumor antigen- and neoepitope-specific CTL. Streamlining the rapid generation of large numbers of T cells in a cost-effective fashion can be a powerful tool for immunotherapy.
3:15 Sponsored Presentation (Opportunity Available)
3:45 Refreshment Break in the Exhibit Hall with Poster Viewing
4:45 Problem-Solving Breakout Discussions
Moving Adoptive T Cell Therapies Toward the End Game
Moderator: Richard S. Kornbluth, M.D., Ph.D., President & CSO, Multimeric Biotherapeutics, Inc.
Focusing CAR, TCR, and TIL for Effective Therapies
Moderator: John S. Bridgeman, Ph.D., Director, Cell Therapy Research, Cellular Therapeutics Ltd.
5:45 Networking Reception in the Exhibit Hall with Poster Viewing
7:00 End of Day
Day 1 | Day 2 | Download Brochure
THURSDAY, APRIL 28
8:00 am Morning Coffee
8:30 Chairpersons Remarks
Richard S. Kornbluth, M.D., Ph.D., President & CSO, Multimeric Biotherapeutics, Inc.
8:35 CD40 Ligand (CD40L) and 4-1BB Ligand (4-1BBL) as Keys to Anti-Tumor Immunity
Richard S. Kornbluth, M.D., Ph.D., President & CSO, Multimeric Biotherapeutics, Inc.
CD40 ligand (CD40L) and 4-1BB ligand (also called CD137L) activate immunity by binding to and clustering their receptors. We have solved the receptor clustering problem by creating fusion proteins that contain many TNFSF trimers. In this talk, we will discuss how soluble multi-trimer forms of TNFSFs such as CD40L and 4-1BBL have many important applications in cancer immunotherapy.
9:05 Immunomodulation of NK Cells to Enhance Anti-Tumor Efficacy
Holbrook Kohrt, Ph.D., Assistant Professor, Medicine, Stanford University
We have recently demonstrated that ADCC function can be augmented by a second antibody against CD137, an NK/macrophage/T cell activation molecule which is expressed following exposure to antibody-bound tumor cells. Agonistic anti-CD137 synergized with anti-CD20 in a syngeneic murine, CD20+ lymphoma model. Since anti-human CD137 antibodies are now becoming clinically available, this strategy can be applied to any tumor with a proven monoclonal treatment including lymphoma, breast, colorectal, and head and neck cancers.
Sadly, we have learned that Dr. Holbrook Kohrt, a remarkable physician-scientist, lost his battle with hemophilia on February 24, 2016. We extend our sincere condolences to his family, friends, and the scientific community.
An alternate speaker will be announced at a future date.
9:35 Sponsored Presentation (Opportunity Available)
10:05 Coffee Break in the Exhibit Hall with Poster Viewing
11:05 Late Breaking Presentation
11:35 Engineering Human T Cell Circuitry
Alex Marson, Ph.D., UCSF Sandler Fellow, University California, San Francisco
T cell genome engineering holds great promise for cancer immunotherapies and for cell-based treatments for immune deficiencies, autoimmune diseases and HIV. We have overcome the poor efficiency of CRISPR/Cas9 genome engineering in primary human T cells using Cas9:single-guide RNA ribonucleoproteins (Cas9 RNPs). Cas9 RNPs can promote targeted genome sequence replacement in primary T cells by homology-directed repair (HDR), which was previously unattainable with CRISPR/Cas9. This provides technology for diverse experimental and therapeutic applications.
12:05 pm Engineering the Genome of CAR T Cells: From Therapeutic Procedures to Products
Andr Choulika, Ph.D., CEO and Chairman, Cellectis
Cellectis therapeutics programs are focused on developing products using TALEN-based gene editing platform to develop genetically modified T cells that express a Chimeric Antigen Receptors (CAR) for cancer treatment. The first product, UCART19, T cells has been gene-edited to suppress GvHD and enable resistance to an Alemtuzumab treatment. The objective of this first product is to convert the CART cell therapy for an autologous approach to an off-the-shelve allogeneic CART product that can be produced in a cost effective fashion, stored, shipped anywhere in the world and immediately available to patient with an immediate unmet medical need.
12:35 End of Adoptive T Cell Therapy
5:15 Registration for Dinner Short Courses
Day 1 | Day 2 | Download Brochure
Read the rest here:
Adoptive T Cell Therapy Conference
- Goodie Mob - Cell Therapy Instrumental - April 2nd, 2011 [April 2nd, 2011]
- Dogged by pain -- stem cell therapy for dogs - April 3rd, 2011 [April 3rd, 2011]
- SIRA: Could Stem Cell Therapy Renew Your Body Cells? – Affordable ... - April 22nd, 2011 [April 22nd, 2011]
- SIRA: Could Stem Cell Therapy Renew Your Body Cells? - April 22nd, 2011 [April 22nd, 2011]
- Stem Cell Therapy for Kidney Failure - May 13th, 2011 [May 13th, 2011]
- Dogs now getting stem cell therapy - May 19th, 2011 [May 19th, 2011]
- Goodie Mob - Cell Therapy Official Music Video (VJ CodyDietz.com ReMiX) - May 20th, 2011 [May 20th, 2011]
- Stem Cell Therapy for Autism - May 20th, 2011 [May 20th, 2011]
- Dog Undergoes Stem Cell Therapy - May 20th, 2011 [May 20th, 2011]
- Stem Cell Therapy for Cerebral Palsy - May 22nd, 2011 [May 22nd, 2011]
- Stem Cell Therapy for Type II Diabetes - May 31st, 2011 [May 31st, 2011]
- Stem Cell Therapy Success - May 31st, 2011 [May 31st, 2011]
- Heart Failure Patient After Adult Stem Cell Therapy - June 1st, 2011 [June 1st, 2011]
- Stem Cell Therapy for Rheumatoid Arthritis - June 3rd, 2011 [June 3rd, 2011]
- Stem Cell Therapy for Critical Limb Ischemia - June 12th, 2011 [June 12th, 2011]
- Stem Cell Therapy Cream: Less Wrinkles In 30 Days or Less Anti-Wrinkle Cream That Works - June 12th, 2011 [June 12th, 2011]
- Stem Cell Therapy for Multiple Sclerosis - June 13th, 2011 [June 13th, 2011]
- Clinical Advances in Adult Stem Cell Therapy: Dr. Jorge Paz - June 17th, 2011 [June 17th, 2011]
- Stem Cell Injection Treatment - Stem Cell Therapy - June 21st, 2011 [June 21st, 2011]
- Stem Cell Therapy for Spinal Cord Injury - Injured Airline Pilot Flies Again - July 1st, 2011 [July 1st, 2011]
- Documentary: Stem Cell Therapy for Muscular Dystrophy - Ryan Benton's Story - July 1st, 2011 [July 1st, 2011]
- Documentary: Stem Cell Therapy for Muscular Dystrophy - Ryan Benton's Story - July 1st, 2011 [July 1st, 2011]
- XCell-Center Stem Cell Therapy Christmas Video 2010 - July 2nd, 2011 [July 2nd, 2011]
- Stem Cell Therapy for Stroke - Gary Steinberg, Stanford University - July 9th, 2011 [July 9th, 2011]
- Stem Cell Therapy Injections - July 9th, 2011 [July 9th, 2011]
- Stem Cell Therapy MS: Sam Harrell and The Superbowl - July 13th, 2011 [July 13th, 2011]
- Adult Stem Cell Therapy Clinical Advances - Dr. Jorge Paz in San Diego, CA March 2011 - July 14th, 2011 [July 14th, 2011]
- Lou Gehrig's Disease (ALS): UCSD Team's Stem Cell Therapy Rationale - July 15th, 2011 [July 15th, 2011]
- Lou Gehrig's Disease (ALS): UCSD Team's Stem Cell Therapy Rationale - July 15th, 2011 [July 15th, 2011]
- Stem Cell Therapy--Hillcrest Animal Hospital - July 18th, 2011 [July 18th, 2011]
- Regenerative Medicine With Stem Cell Therapy Injections at an Arizona pain clinic (602) 507-6550 - July 19th, 2011 [July 19th, 2011]
- Bone Marrow Aspiration - Stem Cell Therapy - July 19th, 2011 [July 19th, 2011]
- The New World of Medicine: Stem Cell Therapy - July 29th, 2011 [July 29th, 2011]
- Post Stem Cell Therapy Video for Cerebral Palsy - August 3rd, 2011 [August 3rd, 2011]
- Lou Gehrig's Disease (ALS): Stem Cell Therapy - A Patient's Perspective - August 5th, 2011 [August 5th, 2011]
- Lou Gehrig's Disease (ALS): Stem Cell Therapy - A Patient's Perspective - August 5th, 2011 [August 5th, 2011]
- Stroke Victim Improved With Stem Cell Therapy. More at http://www.stemcellfusion.com - August 9th, 2011 [August 9th, 2011]
- WAVE3 News Adipose Stem Cell Therapy - August 14th, 2011 [August 14th, 2011]
- Embryonic stem cell therapy in China (www.esctherapy.com) - August 17th, 2011 [August 17th, 2011]
- Ying Liu discusses IPS cell therapy for ALS - August 17th, 2011 [August 17th, 2011]
- KO Clancy - August 24th, 2011 [August 24th, 2011]
- Stem cell therapy in Guatemala - (closer than China) - August 26th, 2011 [August 26th, 2011]
- ATP Cell Therapy - August 27th, 2011 [August 27th, 2011]
- Dr. Craig Saunders Adult Stem Cell Therapy - August 28th, 2011 [August 28th, 2011]
- Spinal Cord Injury - Stem Cell Therapy - August 29th, 2011 [August 29th, 2011]
- Stem Cell Therapy For Alzheimer's/Dementia - September 13th, 2011 [September 13th, 2011]
- Stem Cell Therapy For Alzheimer's/Dementia - September 13th, 2011 [September 13th, 2011]
- Stem Cell Therapy (Regenerative Medicine) in New Jersey - September 17th, 2011 [September 17th, 2011]
- Clinical Advances in Adult Stem Cell Therapy - Dr. Jorge Paz Rodriguez (Miami) - September 23rd, 2011 [September 23rd, 2011]
- Stem Cell Therapy Skin Repair and Anti-Wrinkle Cream - September 25th, 2011 [September 25th, 2011]
- Cardiac Stem Cell Therapy - September 26th, 2011 [September 26th, 2011]
- Adult Stem Cell Therapy for Multiple Sclerosis - September 26th, 2011 [September 26th, 2011]
- SENS5 - Cellular Therapy for Intestinal Regeneration - September 29th, 2011 [September 29th, 2011]
- channel 10 news stem cell therapy for hair loss part 2.flv - October 4th, 2011 [October 4th, 2011]
- Multiple Sclerosis Stem Cell Therapy News Coverage - October 4th, 2011 [October 4th, 2011]
- Stem-Cell-Therapy-in-China.wmv - October 5th, 2011 [October 5th, 2011]
- Adickes: Stem cell therapy - October 5th, 2011 [October 5th, 2011]
- Don Reed: Why we need new stem cell therapies and how you can help - October 5th, 2011 [October 5th, 2011]
- Repair Your Joint Injuries With Stem Cell Therapy | Los Angeles | Beverly Hills | Hollywood - October 6th, 2011 [October 6th, 2011]
- Repair Your Joint Injuries With Stem Cell Therapy | Los Angeles | Beverly Hills | Hollywood - October 6th, 2011 [October 6th, 2011]
- Ovation Cell Therapy Review (request) - October 6th, 2011 [October 6th, 2011]
- Glazer's Edge: Peyton's Stem Cells - October 6th, 2011 [October 6th, 2011]
- Glazer's Edge: Peyton's Stem Cells - October 6th, 2011 [October 6th, 2011]
- The Spinal Cord Journey - Stem cell therapy stories from three spinal cord injury patients - October 6th, 2011 [October 6th, 2011]
- Goodie Mob - Cell Therapy - Video - October 13th, 2011 [October 13th, 2011]
- Randolph veterinarian uses new stem cell therapy on ailing pets - Video - October 13th, 2011 [October 13th, 2011]
- Stem Cell Therapy for Autism - Video - October 13th, 2011 [October 13th, 2011]
- 1 month after using Ovation Hair Cell Therapy and the results are...... - Video - October 13th, 2011 [October 13th, 2011]
- Stem Cell Series: Part 1 - Video - October 15th, 2011 [October 15th, 2011]
- Stem Cell Therapy for Multiple Sclerosis (MS patient) - Video - October 15th, 2011 [October 15th, 2011]
- Affordable Stem Cell Therapy in Guatemala (2hrs from Miami) - Video - October 16th, 2011 [October 16th, 2011]
- Duffy Update, Post Stem Cell Therapy - Video - October 18th, 2011 [October 18th, 2011]
- Duffy Gets Stem Cell Therapy - Video - October 18th, 2011 [October 18th, 2011]
- Adult Stem Cell Therapy for Congestive Heart Failure - October 20th, 2011 [October 20th, 2011]
- CELL THERAPY - Video - October 23rd, 2011 [October 23rd, 2011]
- Stem Cell Therapy in Cardiac Disease - Video - October 25th, 2011 [October 25th, 2011]
- Stem Cell Therapy for Rheumatoid Arthritis - Community Outreach Dallas - Darnell Morris - Video - October 25th, 2011 [October 25th, 2011]
- UMBILICAL CORD STEM CELL THERAPY - Video - October 27th, 2011 [October 27th, 2011]
- Stem Cell Therapy for Multiple Sclerosis Stimulates IDO - Video - October 27th, 2011 [October 27th, 2011]
- Goodie Mob - Cell Therapy ( Killuminati Music ) - Video - October 27th, 2011 [October 27th, 2011]